CoChat
Sign Up
Cited by 97

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Association of Treatment With Medications for Opioid Use Disorder With Mortality After Hospitalization for Injection Drug Use–Associated Infective Endocarditis

Kimmel, Simeon D., Walley, Alexander Y., Li, Yijing, Linas, Benjamin P., Lodi, Sara, Bernson, Dana, Weiss, Roger D., Samet, Jeffrey H., Larochelle, Marc R.·2020·JAMA Network Open
DOI 10.1001/jamanetworkopen.2020.16228PMC PMC7557514
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamanetworkopen.2020.16228

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Receipt of Medication for Opioid Use Disorder (MOUD) Before and After Hospitalization for Injection Drug Use–Associated Infective Endocarditis From July 2011 to June 2015 Receipt of MOUD did not include the month of hospitalization.
Figure 1. Receipt of Medication for Opioid Use Disorder (MOUD) Before and After Hospitalization for Injection Drug Use–Associated Infective Endocarditis From July 2011 to June 2015 Receipt of MOUD did not include the month of hospitalization.CC BY · PubMed Central
Figure 2. Monthly Receipt of Medication for Opioid Use Disorder (MOUD) by Those Who Did and Did Not Receive MOUD Within 3 Months of Hospital Discharge for Injection Drug Use–Associated Infective Endocarditis (IDU-IE) From July 2011 to June 2015 Primary MOUD exposure was defined as MOUD receipt in months 1 through 3 (shaded area). Month 0 was excluded because MOUD could have been received before hospitalization.
Figure 2. Monthly Receipt of Medication for Opioid Use Disorder (MOUD) by Those Who Did and Did Not Receive MOUD Within 3 Months of Hospital Discharge for Injection Drug Use–Associated Infective Endocarditis (IDU-IE) From July 2011 to June 2015 Primary MOUD exposure was defined as MOUD receipt in months 1 through 3 (shaded area). Month 0 was excluded because MOUD could have been received before hospitalization.CC BY · PubMed Central
Figure 3. Kaplan-Meier and Extended Kaplan-Meier Cumulative Incidence of All-Cause Mortality by Monthly Exposure to Medication for Opioid Use Disorder (MOUD) for Injection Drug Use–Associated Infective Endocarditis (IDU-IE) From July 2011 to June 2015 Models 1 to 3 included only individuals who survived 2 months after hospitalization for IDU-IE.
Figure 3. Kaplan-Meier and Extended Kaplan-Meier Cumulative Incidence of All-Cause Mortality by Monthly Exposure to Medication for Opioid Use Disorder (MOUD) for Injection Drug Use–Associated Infective Endocarditis (IDU-IE) From July 2011 to June 2015 Models 1 to 3 included only individuals who survived 2 months after hospitalization for IDU-IE.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 21

  1. Deo, 2018, Admissions for infective endocarditis in intravenous drug users., J Am Coll Cardiol, 71, 1596, 10.1016/j.jacc.2018.02.011 · DOI
  2. Leahey, 2019, High morbidity and mortality among patients with sentinel admission for injection drug use-related infective endocarditis., Open Forum Infect Dis, 6, 10.1093/ofid/ofz089 · DOI
  3. Rodger, 2018, Clinical characteristics and factors associated with mortality in first-episode infective endocarditis among persons who inject drugs., JAMA Netw Open, 1, 10.1001/jamanetworkopen.2018.5220 · DOI
  4. Kimmel, 2019, Effect of publicly reported aortic valve surgery outcomes on valve surgery in injection drug– and non–injection drug-associated endocarditis., Clin Infect Dis
  5. Springer, 2018, Integrating treatment at the intersection of opioid use disorder and infectious disease epidemics in medical settings: a call for action after a National Academies of Sciences, Engineering, and Medicine Workshop., Ann Intern Med, 169, 335, 10.7326/M18-1203 · DOI
  6. Suzuki, 2016, Medication-assisted treatment for hospitalized patients with intravenous-drug-use related infective endocarditis., Am J Addict, 25, 191, 10.1111/ajad.v25.3 · DOI
  7. Barocas, 2020, Outcomes associated with medications for opioid use disorder among persons hospitalized for infective endocarditis., Clin Infect Dis
  8. Lee, 2018, Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial., Lancet, 391, 309, 10.1016/S0140-6736(17)32812-X · DOI · Paper page
  9. Krupitsky, 2011, Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial., Lancet, 377, 1506, 10.1016/S0140-6736(11)60358-9 · DOI · Paper page
  10. Suzuki, 2019, Long-term Outcomes of Injection Drug-related Infective Endocarditis Among People Who Inject Drugs., J Addict Med, 1
  11. Thakarar, 2019, Mortality, morbidity, and cardiac surgery in Injection Drug Use (IDU)-associated versus non-IDU infective endocarditis: The need to expand substance use disorder treatment and harm reduction services., PLoS One, 14, 10.1371/journal.pone.0225460 · DOI
  12. Schiff, 2018, Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts., Obstet Gynecol, 132, 466, 10.1097/AOG.0000000000002734 · DOI · Paper page
  13. Bagley, 2017, Addressing stigma in medication treatment of adolescents with opioid use disorder., J Addict Med, 11, 415, 10.1097/ADM.0000000000000348 · DOI
  14. Chatterjee, 2019, Non-fatal opioid-related overdoses among adolescents in Massachusetts 2012-2014., Drug Alcohol Depend, 194, 28, 10.1016/j.drugalcdep.2018.09.020 · DOI
  15. Ball, 2017, Validation of an algorithm to identify infective endocarditis in people who inject drugs., Med Care, 1
  16. Kimmel, 2020, Rejection of patients with opioid use disorder referred for post-acute Medical care before and after an anti-discrimination settlement in Massachusetts., J Addict Med, 10.1097/ADM.0000000000000693 · DOI
  17. Rosenthal, 2016, Suboptimal addiction interventions for patients hospitalized with injection drug use-associated infective endocarditis., Am J Med, 129, 481, 10.1016/j.amjmed.2015.09.024 · DOI · Paper page
  18. Trowbridge, 2017, Addiction consultation services—linking hospitalized patients to outpatient addiction treatment., J Subst Abuse Treat, 79, 1, 10.1016/j.jsat.2017.05.007 · DOI
  19. Wakeman, 2017, Inpatient addiction consultation for hospitalized patients increases post-discharge abstinence and reduces addiction severity., J Gen Intern Med, 32, 909, 10.1007/s11606-017-4077-z · DOI
  20. Substance Abuse and Mental Health Services Administration, 2018, Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63
  21. Mattick, 2003, Cochrane Database of Systematic Reviews.

Cited by

Sorted by citations

See all 97

Metadata

Authors
Kimmel, S. D., Walley, A. Y., Li, Y., Linas, B. P., Lodi, S., Bernson, D., Weiss, R. D., Samet, J. H., & Larochelle, M. R.
Affiliations
  • Section of General Internal Medicine, Department of Medicine, Boston Medical Center, Boston, Massachusetts
  • Section of Infectious Diseases, Department of Medicine, Boston Medical Center, Boston, Massachusetts
  • Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts
  • Massachusetts Department of Public Health, Boston, Massachusetts
  • Substance Use Disorders Division, McLean Hospital, Belmont, Massachusetts
Venue
JAMA Network Open
Publisher
American Medical Association (AMA)
Published
2020-10-14
Volume
3
Issue
10
Pages
e2016228
ISSN
2574-3805
DOI
10.1001/jamanetworkopen.2020.16228
PMC
PMC7557514
Cited by
97
References
5
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review